ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck’s ICT01 Receives FDA Orphan Drug Designation for Treatment of Acute Myeloid Leukemia
Science & Medicine 
Read more
ImCheck Therapeutics Named to French Tech 120 for Sixth Consecutive Year
Leadership & Corporate 
Read more
ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025
Science & Medicine 
Read more

SOHO 2025 Annual Meeting

From  Sep 03, 2025  to  Sep 06, 2025 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news